Table 5.

Clinical trials with solnatide (AP301). (https://clinicaltrials.gov/, https://eudract.ema.europa.eu/, accessed on 27 March 2023).

Study Title/ Number	Intervention	Trial Phase/ Recruitment Status	Disease/ Condition
Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury NCT01627613 EudraCT Nr. 2012-001863-64	AP301 Saline Solution	Phase 2 2012–2019 completed	Acute Lung Injury (ALI)
Study in Intensive Care Patients Regarding the Effect of Inhaled AP301 After Primary Graft Dysfunction After Lung Transplantation NCT02095626 EudraCT Nr. 2013-000716-21	AP301 Saline Solution	Phase 2 2014–2019 completed	Primary Graft Dysfunction
Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS NCT03567577	Solnatide 25 mg powder (solution for inhalation) 0.9% Saline Solution	Phase 2 2018–2022 recruiting	ARDS
COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-CoV-2 positive patients with moderate-to-severe ARDS—a pilot-trial. EudraCT Nr. 2020-001244-26	Solnatide Powder for nebuliser suspension (inhalation) Placebo	Phase 2 2020–2021 Prematurely ended	Oedema in SARS-Co-2 positive patients with ARDS